Dr. Butera is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
593 Eddy St
Apc 138
Providence, RI 02903Phone+1 401-444-5391Fax+1 401-444-8918
Education & Training
Brown UniversityFellowship, Hematology and Medical Oncology, 1997 - 2000- Brown UniversityResidency, Internal Medicine, 1994 - 1997
University of Massachusetts Medical SchoolClass of 1994
Certifications & Licensure
RI State Medical License 1995 - 2026- American Board of Internal Medicine Hematology
Awards, Honors, & Recognition
- Top MD Consumers Checkbook
Clinical Trials
- Study of Infusion of Blood Cells (Lymphocytes) to Stimulate the Immune System to Fight Leukemia/Lymphoma Start of enrollment: 2013 Mar 01
- Molecular Testing of Cancer by Integrated Genomic, Transcriptomic, and Proteomic Analysis Start of enrollment: 2013 May 01
Publications & Presentations
PubMed
- 46 citationsPrognosis in primary effusion lymphoma is associated with the number of body cavities involved.Jorge J. Castillo, Helen Shum, Majid Lahijani, Eric S. Winer, James N. Butera
Leukemia & Lymphoma. 2012-05-16 - 34 citationsAre we training our fellows adequately in delivering bad news to patients? A survey of hematology/oncology program directorsHannah D. Hebert, James N. Butera, Jorge J. Castillo, Anthony Mega
Journal of Palliative Medicine. 2007-06-20 - 94 citationsPrognostic Factors in Chemotherapy-Treated Patients with HIV-Associated Plasmablastic LymphomaJorge J. Castillo, Eric S. Winer, Dariusz Stachurski, Kimberly Perez, Melhem Jabbour
The Oncologist. 2010-03-01
Abstracts/Posters
- Tumor-Specific Cell-Free DNA (cfDNA) in the Cerebrospinal Fluid (CSF) Detects Cytologically Occult Central Nervous System (CNS) Involvement in Aggressive LymphomasJames Butera, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- BrUOG 345: Fractionated Gemtuzumab Ozogamicin Followed By Non-Engraftment Donor Leukocyte Infusions for Relapsed/Refractory Acute Myeloid LeukemiaJames Butera, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
